Research ArticleIUPHAR Nomenclature Report
International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands
Anthony P. Davenport, Stephen P. H. Alexander, Joanna L. Sharman, Adam J. Pawson, Helen E. Benson, Amy E. Monaghan, Wen Chiy Liew, Chidochangu P. Mpamhanga, Tom I. Bonner, Richard R. Neubig, Jean Philippe Pin, Michael Spedding and Anthony J. Harmar
Eliot H. Ohlstein, ASSOCIATE EDITOR
Pharmacological Reviews July 2013, 65 (3) 967-986; DOI: https://doi.org/10.1124/pr.112.007179
Anthony P. Davenport
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Stephen P. H. Alexander
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Joanna L. Sharman
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Adam J. Pawson
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Helen E. Benson
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Amy E. Monaghan
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Wen Chiy Liew
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Chidochangu P. Mpamhanga
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Tom I. Bonner
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Richard R. Neubig
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Jean Philippe Pin
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Michael Spedding
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Anthony J. Harmar
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Eliot H. Ohlstein
Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom (A.P.D.); School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, United Kingdom (S.P.H.A.); The University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom (J.L.S., A.J.P., H.E.B., A.E.M., W.C.L., C.P.M., A.J.H.); Section on Functional Neuroscience, National Institute of Mental Health, Bethesda, Maryland (T.I.B.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Department of Molecular Pharmacology, Institute of Functional Genomics, CNRS UMR5203, Universities Montpellier, Montpellier, France (J.P.P.); and Les Laboratoires Servier, Suresnes, France (M.S.)
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleIUPHAR Nomenclature Report
G-Protein-Coupled Receptor List Update
Anthony P. Davenport, Stephen P. H. Alexander, Joanna L. Sharman, Adam J. Pawson, Helen E. Benson, Amy E. Monaghan, Wen Chiy Liew, Chidochangu P. Mpamhanga, Tom I. Bonner, Richard R. Neubig, Jean Philippe Pin, Michael Spedding and Anthony J. Harmar
Pharmacological Reviews July 1, 2013, 65 (3) 967-986; DOI: https://doi.org/10.1124/pr.112.007179
Research ArticleIUPHAR Nomenclature Report
G-Protein-Coupled Receptor List Update
Anthony P. Davenport, Stephen P. H. Alexander, Joanna L. Sharman, Adam J. Pawson, Helen E. Benson, Amy E. Monaghan, Wen Chiy Liew, Chidochangu P. Mpamhanga, Tom I. Bonner, Richard R. Neubig, Jean Philippe Pin, Michael Spedding and Anthony J. Harmar
Pharmacological Reviews July 1, 2013, 65 (3) 967-986; DOI: https://doi.org/10.1124/pr.112.007179
Jump to section
- Article
- Abstract
- I. Introduction
- II. Criteria for Deorphanization
- III. Recommendations for Formal Receptor Nomenclature Based on New Pairings of Orphan Receptors with Cognate Ligands
- IV. Pairings of Orphan Receptors with Cognate Ligands Reported by a Single Paper or Where a Formal Pairing Is Yet To Be Agreed
- V. Orphan Receptors with Activity in Absence of an Endogenous Ligand, Activation by Surrogate Ligands, or Significant Phenotype in Genetically Modified Animals
- VI. Pseudogenes
- VII. Conclusion
- Acknowledgments
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement